|
CL2025003637A1
(es)
|
|
Anticuerpos anti-tgf-beta 1 latente y métodos de uso.
|
|
BR102022025291A2
(https=)
|
|
|
|
BR102023014872A2
(https=)
|
|
|
|
BR102023012440A2
(https=)
|
|
|
|
BR102023010976A2
(https=)
|
|
|
|
BR102023008688A2
(https=)
|
|
|
|
BR102023007252A2
(https=)
|
|
|
|
BR102023005164A2
(https=)
|
|
|
|
BR102023001877A2
(https=)
|
|
|
|
BR102023000289A2
(https=)
|
|
|
|
BR102022026909A2
(https=)
|
|
|
|
BR102022023461A2
(https=)
|
|
|
|
BR202022009269U2
(https=)
|
|
|
|
BR202022005961U2
(https=)
|
|
|
|
BR202022000931U2
(https=)
|
|
|
|
CN307048462S
(https=)
|
|
|
|
BY13176U
(https=)
|
|
|
|
CN307047758S
(https=)
|
|
|
|
CN307047159S
(https=)
|
|
|
|
BY13167U
(https=)
|
|
|
|
CN307046813S
(https=)
|
|
|
|
CN307045796S
(https=)
|
|
|
|
CN307045517S
(https=)
|
|
|
|
BY13166U
(https=)
|
|
|
|
CN307045454S
(https=)
|
|
|